Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Naoki Kimura *et al.*	
		Filing Date April 20, 2007	Group Art Unit 1643

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	11/910,117	8/28/2007	Igawa *et al.*			
	2	12/307,042	12/30/2008	Kimura *et al.*			
	3	5,837,242	11/1998	Holliger *et al.*			
	4	5,840,344	11/24/1998	Fukushima			
	5	5,885,574	03/23/1999	Elliott			
	6	6,126,980	10/3/2000	Smith *et al.*			
	7	6,579,692	06/17/2003	Fukushima			
	8	6,719,972	04/13/2004	Gribben *et al.*			
	9	6,759,043	07/06/2004	Fukushima			
	10	2003/0147894	08/07/2003	Fukushima *et al.*			
	11	2003/0157100	08/2003	Fukushima *et al.*			
	12	2003/0157577	08/2003	Fukushima *et al.*			
	13	2003/0202975	10/2003	Tedder			
	14	2003/0211108	11/2003	Fukushima *et al.*			
	15	2004/0001828	1/1/2004	Tuscano *et al.*			
	16	2004/0073013	04/2004	Fukushima *et al.*			
	17	2005/0214278	9/29/2005	Kakuta *et al.*			
	18	2005/0267222	12/1/2005	Iwata *et al.*			
	19	2009/0028854	01/29/2009	Igawa *et al.*			
	20	2009/0117097	5/7/2009	Igawa *et al.*			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	21	CA 2272245	05/28/1998	Canada				
	22	EP 437 622	07/24/1991	Europe				
	23	EP 0 721 015	07/10/1996	Europe				
	24	EP 1 035 132	09/13/2000	Europe				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	25	EP 0562125	09/29/1993	Europe				
	26	EP 1 396 500	03/10/2004	Europe				
	27	EP 1 262 548	8/10/2008	Europe				
	28	JP 3-41033	02/21/1991	Japan			Abstract only	
	29	JP 7236475	9/12/1995	Japan			Abstract only	
	30	JP 11-092500	04/06/1999	Japan			Abstract only	
	31	JP 2000-95800	04/04/2000	Japan			Abstract only	
	32	JP 2004-292455	10/21/2004	Japan			Abstract only	
	33	WO 91/16928	11/14/1991	WIPO				
	34	WO 92/19759	11/12/1992	WIPO			English abstract	
	35	WO 93/06862	4/15/1993	WIPO			English abstract	
	36	WO 94/13806	06/23/1994	WIPO				
	37	WO 96/36360	11/21/1996	WIPO				
	38	WO 97/01633	1/16/1997	WIPO				
	39	WO 97/32601	9/12/1997	WIPO			English abstract	
	40	WO 98/22136	5/28/1998	WIPO			English abstract	
	41	WO 98/44001	08/10/1998	WIPO				
	42	WO 99/17364	04/08/1999	WIPO				
	43	WO00/53634	09/14/2000	WIPO			English abstract	
	44	WO00/75191	12/14/2000	WIPO				
	45	WO01/77342	10/18/2001	WIPO				
	46	WO02/094880	11/28/2002	WIPO			English abstract	
	47	WO 02/096457	12/05/2002	WIPO				
	48	WO 02/097033	12/05/2002	WIPO				

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	49	WO 03/086324	10/23/2003	WIPO				
	50	WO 04/037293	5/6/2004	WIPO			English abstract	
	51	WO 2006/123724	11/23/2006	WIPO			English abstract	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	52	AVENT *et al.*, "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific," *Biochem. J.*, 251:499-505 (1988)
	53	BARTLEY *et al.*, "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," *Cell*, 77:1117-1124 (1994)
	54	BAZIL *et al.*, "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes," *Blood*, 86:502-511 (1995)
	55	BAZZONI *et al.*, "Chimeric tumor necrosis factor receptors with constitutive signaling activity," *Proc. Natl. Acad. Sci. USA*, 92(12):5376-5580 (1995)
	56	BERGER *et al.*, "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," *Biochemistry*, 18(23):5143-5149 (1979)
	57	BODMER *et al.*, "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," *Nat. Cell Biol.*, 2:241-243 (2000)
	58	BOWIE *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science*, 247:1306-1310 (1990)
	59	BROWN *et al.*, "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," *J. Cell Biology*, 111(6 Pt 1):2785-2794 (1990)
	60	BROWN *et al.*, "Integrin-associated protein (CD47) and its ligands," *Trends Cell Biology*, 11(3):130-135 (2001)
	61	BUCHSBAUM *et al.*, "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," *Clin. Cancer Res.*, 9:3731-3741 (2003)
	62	BURTHEM *et al.*, "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," *Blood*, 84(3):873-882 (1994)
	63	CALDAS *et al.*, "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," *Mol. Immunol.*, 39:941-952 (2003)
	64	CARPENTER *et al.*, "Rational design of stable lyophilized protein formulations: some practical advice," *Pharmaceutical Research*, 14(8):969-975 (1997)
	65	CARPENTER *et al.*, "Rational design of stable lyophilized protein formulations: theory and practice," *Pharma Biotechnol.*, 13:109-133 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	66	CHIEN *et al.*, "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," *Proc. Nat. Acad. Sci. USA*, 86:5532-5536 (1989)
	67	CHIRGWIN *et al.*, "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," *Biochemistry*, 18(24):5294-5299 (1979)
	68	CHUNTHARAPAI *et al.* "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," *J. Immunol.*, 166:4891-4898 (2001)
	69	CLELAND *et al.*, "A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody," *Journal of Pharmaceutical Sciences*, 90(3):310-321 (2001)
	70	COCHLOVIUS *et al.*, "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 x CD19 Tandem Diabody and CD28 Costimulation," *Cancer Res.*, 60:4336-4341 (2000)
	71	COOPER *et al.*, "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," *Proc. Natl. Acad. Sci. USA*, 92:3978-3982 (1995)
	72	DANIEL *et al.*, "Pathway of apoptosis induced in Jurkat T Lymphoblasts by anti-HLA Class I antibodies," *Human Immunology*, 65(3):189-199 (2004)
	73	DE LEON *et al.*, "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," *BMC Cancer*, 9(48):1-9 (2009)
	74	DEGLI-ESPOSTI *et al.*, "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," *J. Exp. Med.*, 186:1165-1170 (1997)
	75	DE SAUVAGE *et al.*, "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," *Nature*, 369:533-538 (1994)
	76	DESPLANCQ *et al.*, "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," *Protein Engineering*, 7(8):1027-1033 (1994)
	77	DE ST. GROTH *et al.*, "Production of Monoclonal Antibodies: Strategy and Tactics," *Journal of Immunological Methods*, 35:1-21 (1980)
	78	DILLMAN, "Monoclonal antibodies for treating cancer," *Ann. Int. Med.*, 11(7):592-603 (1989)
	79	DORAI *et al.*, "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," *Biotechnology*, 12(9):890-897 (1994)
	80	EMERY *et al.*, "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," *J. Biol. Chem.*, 273: 14363-14367 (1998)
	81	FELGENHAUER *et al.* "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," *Nucleic Acids Research*, 18(16):4927 (1990)
	82	FROKJAER *et al.*, "Protein drug stability: a formulation challenge," Nature Rev Drug Discov. 4:298-306 (2005)
	83	FUJIMOTO *et al.*, "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," *Blood*, 86(6):2174-2182 (1995)
	84	FUKUSHIMA *et al.*, "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," *Blood*, 80(8):1914-1922 (1992)

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	85	FUKUSHIMA *et al.*, "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," *Blood*, 94(10):479A (1999)
	86	GALFRE *et al.*, "Preparation of monoclonal antibodies: strategies and procedures," *Methods in Enzymology*, 73:3-46 (1981)
	87	GALFRE *et al.*, "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," *Nature*, 277:131-133 (1979)
	88	GARCIA-GONZALEZ *et al.*, "Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation," *Journal of Immunological Methods,* 111:17-23 (1988)
	89	GIUSTI *et al.*, "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," *Proc. Natl. Acad. Sci. USA*, 84:2926-2930 (1987)
	90	GODING, "Monoclonal Antibodies: Principles and Practice," *Academic Press*, second Ed., 125:129 (1986)
	91	GOMBOTZ *et al.*, "The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone)," *Pharmaceutical Research*, 11(5):624-632 (1994)
	92	GREENSPAN et at., "Defining epitopes: It's not as easy as it seems," *Nature Biotechnology*, 17:936-937 (1999)
	93	GRELL *et al.*, "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis," *Lymphokine and Cytokine Research*, 12(3):143-148 (1993)
	94	GRIFFITH *et al.*, "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," *J. Immunol.*, 162:2597-2605 (1999)
	95	GÜSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," *Methods in Enzymology*, 203:99-121 (1991)
	96	HOLLIGER el at., "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," *Protein Engineering*, 9(3):299-305 (1996)
	97	HOPP *et al.*, "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," *Biotechnology*, 6:1204-1210 (1988)
	98	HORAN *et al.*, "Dimerization of the extracellular domain of granuloycte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," *Biochemistry*, 35:4886-4896 (1996)
	99	HUSTON *et al.*, "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in *Escherichia Coli*," *Proc. Natl. Acad. Sci. USA*, 85:5879-5883 (1988)
	100	ITOH *et al.*, "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," *Cell*, 66:233-243 (1991)
	101	JIANG *et al.*, "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," *J. Biol. Chem.*, 280(6):4656-4662 (2005)
	102	JONES *et al.*, "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions," *Biotechnology*, 9:88-89 (1991)
	103	KEARNEY, *et al.*, "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," *The Journal of Immunology*, 123(4):1548-1550 (1979)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	104	KEEN *et al.*, "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," *Cytotechnology*, 18(3):207-217 (Abstract) (1994)
	105	KIPRIYANOV *et al.*, "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells," *In. J. Cancer,* 77:763-772 (1998)
	106	KOHLER, *et al.*, "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," *Eur. J. Immunol.*, 6:511-519 (1976)
	107	KORTT *et al.*, "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimmer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," *Eur. J. Biochem.*, 221:151-157 (1994)
	108	KORTT *et al.*, "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten- residue linkers form dimmers and with zero-residue linker a trimer," *Protein Engineering*, 10(4):423433 (1997)
	109	KOZAK, M., "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," *J. Mol. Biol.*, 196:947-950 (1987)
	110	LARRICK, *et al.*, "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," *Biotechnology*, 7:934-938 (1989)
	111	LAW *et al.*, "Observations On The Effect Of A Folic-Acid Anatagonist On Transplantable Lymphoid Leukemias In Mice," *Journal of the National Cancer Institute*, 10:179-193 (1949)
	112	LE GALL *et al.*, "Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody," *Protein Engineering Design & Selection,* 17(4):357-366 (2004)
	113	LEE *et al.*, "Reversible dimer formation and stability of the anti-tumour single chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FR-IR spectroscopy," *J. Mol. Biol.*, 320:107-127 (2002)
	114	LEI *et al.*, "Characterization of the *Erwinia Carotovora pelB* Gene and Its Product Pectate Lyase," *Journal of Bacteriology*, 4379-4383 (1987)
	115	LINDBERG *et al.*, "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_v\beta_3$-Dependent Ligand Binding," *The Journal of Cell Biology*, 123(2):485-496, The Rockefeller University Press (1993)
	116	LINDBERG *et al.*, "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," *J. Biol. Chem.*, 269:1567-1570 (1994)
	117	MARGULIES *et al.*, "Somatic Cell Hybridization of Mouse Myeloma Cells," *Cell*, 8:405-415 (1976)
	118	MARIUZZA *et al.*, "The structural basis of antigen-antibody recognition," *Ann. Rev. Biophys. Biophys. Chem.*, 16:139-159 (1987)
	119	MARIUZZA *et al.*, "The Structural Basis of Antigen-Antibody Recognition," *Ann. Rev. Biophys. Chem.*, 16:139-159 (1987)
	120	MARSTERS *et al.*, "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," *Curr. Biol.*, 7:1003-1006 (1997)

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	121	MARTSEV *et al.*, "Antiferritin single-chain antibody: a functional protein with incomplete folding?" *FEBS Letters,* 441:458-462 (1998)
	122	MATEO et at al., "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," *FASEB Journal*, 12(5):A1082 (1998)
	123	MAWBY *et al.*, "Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," *Biochem. J.*, 304:525-530 (1994)
	124	METHIA *et al.*, "Oligodeoxynucleotides Antisense to the Proto-Oncogene *c-Mpl* Specifically Inhibit In Vitro Megakaryocytopoiesis," *Blood*, 82(5):1395-1401 (1993)
	125	MILILI *et al.*, "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of *Bona Fide* Heavy Chains," *Eur. J. Immunol.*, 26:63-69 (1996)
	126	MIZUSHIMA *et al.*, "pEF-BOS, a Powerful Mammalian Expression Vector," *Nucleic Acids Research*, 18(17):5322 (1990)
	127	MOORE *et al.*, "Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor," *Biochemistry*, 38:13960-13967 (1999)
	128	MORI *et al.*, "Human normal hepatocytes are suspectible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," *Cell Death and Differentiation*, 11:203-207 (2004)
	129	MULLIGAN *et al.*, "Synthesis of Rabbit ß-Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 ß-Globin Recombinant Genome," *Nature*, 277:108-114 (1979)
	130	NAKAYAMA *et al.*, "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," *Journal of Molecular Medicine*, 83:316-320 (2005)
	131	NGO *et al.*, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox ," *The Protein Folding Problem and Tertiary Structure Prediction*, Merz, Jr. *et al.* Editors, Birkhauser Boston, 433-506 (1994)
	132	O'BRIEN *et al.*, "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," *Biochim. Soc. Trans.*, 14(6):1021-1023 (1986)
	133	OHTSUKA *et al.*, "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway," *Oncogene*, 22:2034-2044 (2003)
	134	PAN *et al.*, "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," *Science*, 277:815-818 (1997)
	135	PAN *et al.*, "The Receptor for the Cytotoxic Ligand TRAIL," *Science*, 276:111-113 (1997)
	136	PAUL, *Fundamental Immunology*, Raven Press, NY, Chapter 8, p. 242 (1993)
	137	PETTERSON *et al.*, "CD47 Signals T Cell Death," *J. Immunol.*, 7031-7040 (1999)
	138	PETTERSON, "CD47 and death signaling in the immune system," *Apoptosis*, 5:299-306 (2000)
	139	REINHOLD *et al.*, "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," *J. Cell Science*, 108:3419-3425 (1995)
	140	RIECHMANN *et al.*, "Reshaping Human Antibodies for Therapy," *Nature*, 332:323-327 (1988)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	141	REITER *et al.*, "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv," *Protein Engineering*, 7(5):697-704 (1994)
	142	REITER *et al.*, "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," *Biochemistry*, 33:5451-5459 (1994)
	143	ROUE *et al.* "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release," *Biochimie.*, 85:741-746 (2003)
	144	ROZSNYAY *et al.*, "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphroylation of a distinct group of proteins," *Immunology Lett.*, 37(2-3):197-205 (1993)
	145	SATO *et al.*, "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," *Cancer Research*, 53:851-856 (1993)
	146	SCHICKEL, *et al.*, "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," *Biochem. Cell. Biol.*, 80(2):169-176 (2002)
	147	SCHWARTZ *et al.*, "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," *J. Biol. Chem.*, 268(27):19931-19934 (1993)
	148	SCHMIDT *et al.*, "A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor," *Int. J. Cancer*, 65(4):538-546 (1996)
	149	SHARMA *et al.*, "Study of IgM aggregation in serum of patients with macroglobulinemia," *Clin Chem Lab Med,* 38(8):759-764 (2000)
	150	SHERIDAN *et al.*, "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," *Science*, 277:818-821 (1997)
	151	SHIGETA *et al.*, "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," *Clin. Exp. Immunol.*, 42:458-462 (1980)
	152	SHULMAN *et al.*, "A better cell line for making hybridomas secreting specific antibodies," *Nature*, 276:269-270 (1978)
	153	SOUYRI, M., "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," *Seminars in Hematology*, 35(3):222-231 (1998)
	154	SPAARGAREN *et al.*, "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase," *The J. Biol. Chem.*, 266(3):1733-1739 (1981)
	155	STANCOVSKI *et al.*, "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," *Proc. Natl. Acad. Sci. USA*, 88:8691-8695 (1991)
	156	TROWBRIDGE, I.S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," *J. Exp. Med.*, 148:313-323 (1978)
	157	VAN GEELEN *et al.*, "Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines," *Br. J. Cancer*, 89(2):363-373 (2003)
	158	VERMA *et al.*, "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems," *Journal of Immunological Methods*, 216:165-181 (1998)
	159	WALCZAK *et al.*, "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," *EMBO J.*, 16:5386-5397 (1997)
	160	WANG *et al.*, "Instability, stabilization, and formulation of liquid protein pharmaceuticals," *International Journal of Pharmaceutics,* 185:129-188 (1999)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	161	WANG *et al.*, "Lyophilization and development of solid protein pharmaceuticals," *International Journal of Pharmaceutics,* 203:1-60 (2000)
	162	WANG *et al.*, "Protein aggregation and its inhibition in biopharmaceutics," *International Journal of Pharmaceutics,* 289:1-30 (2005)
	163	WELLS, "Perspectives in Biochemistry," *Biochemistry*, 29(37):8509-8517 (1990)
	164	WILEY *et al.*, "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," *Immunity*, 3:673-682 (1995)
	165	WINKLER *et al.*, "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," *J. Immunol.*, 265:4505-4514 (2000)
	166	XIE *et al.*, "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv," *Nature Biotechnology*, 15(8):768-771 (1997)
	167	YANABU *et al.*, "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody," *Blood*, 89(5):1590-1598 (1997)
	168	YARDEN *et al.*, "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," *Biochemistry*, 26(5):1434-1442 (1987)
	169	YELTON *et al.*, "Fusion of Mouse Myeloma and Spleen Cells," *Current Topics in Microbiology and Immunology*, 81:1-7 (1978)
	170	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/530,696, mailed October 19, 2006, 8 pages
	171	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S. App. Ser. No. 10/530,696, filed November 16, 2006, 1 page
	172	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed December 21, 2006, 19 pages
	173	FISH & RICHARDSON P.C., Response to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed April 23, 2007, 16 pages
	174	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed August 8, 2007, 13 pages
	175	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/530,696, mailed November 26, 2007, 3 pages
	176	FISH & RICHARDSON P.C., Response to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed December 6, 2007, 12 pages
	177	U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696, mailed December 14, 2007, 4 pages
	178	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed February 5, 2008, 9 pages
	179	FISH & RICHARDSON, Response to Office Action dated February 5, 2008 in U.S. App. Ser. No. 10/530,696, filed August 5, 2008, 7 pages
	180	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed November 17, 2008, 18 pages
	181	FISH & RICHARDSON, Response to Office Action dated November 17, 2008 in U.S. App. Ser. No. 10/530,696, filed February 17, 2009, 14 pages
	182	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2003/013063, mailed November 18, 2003, 2 pages

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	183	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2003/013063, dated February 6, 2004, 4 pages
	184	EPO EXAMINER W. BERNHARDT, European Search Report for App. Ser. No. EP 03 75 1456, dated April 4, 2006, 2 pages
	185	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed June 8, 2009, 10 pages
	186	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Restriction Requirement in U.S. App. Ser. No. 10/548,727, mailed April 12, 2007, 6 pages
	187	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App. Ser. No. 10/548,727, filed May 3, 2007, 1 page
	188	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed August 3, 2007, 21 pages
	189	FISH & RICHARDSON P.C., Reply to Office Action dated August 3, 2007 in U.S. App. Ser. No. 10/548,727, filed January 15, 2008, 15 pages
	190	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Final Office Action in U.S. App. Ser. No. 10/548,727, mailed April 29, 2008, 23 pages
	191	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Advisory Action in U.S. App. Ser. No. 10/548,727, mailed September 24, 2008, 6 pages
	192	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed January 28, 2009, 16 pages
	193	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/003334, mailed June 15, 2004, 3 pages
	194	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/003334, dated May 2, 2005, 6 pages
	195	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/550,934, mailed November 21, 2007, 7 pages
	196	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 21, 2007 in U.S. App. Ser. No. 10/550,934, filed April 16, 2008, 2 pages
	197	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed June 12, 2008, 27 pages
	198	FISH & RICHARDSON P.C., Response to Office Action dated June 12, 2008 in U.S. App. Ser. No. 10/550,934, filed December 12, 2008, 45 pages
	199	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/550,934, mailed March 16, 2009, 19 pages
	200	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/004696, mailed July 27, 2004, 5 pages
	201	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/004696, dated February 9, 2005, 10 pages
	202	EPO EXAMINER N. FAVRE, European Search Report for App. Ser. No. EP 04 72 4770, dated March 31, 2006, 4 pages
	203	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed June 27, 2008, 6 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Naoki Kimura *et al.*	
		Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	204	FISH & RICHARDSON P.C., Response to Restriction Requirement dated June 27, 2008 in U.S. App. Ser. No. 10/551,504, filed September 29, 2008, 13 pages
	205	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed December 16, 2008, 5 pages
	206	FISH & RICHARDSON P.C., Response to Restriction Requirement dated December 16, 2008 in U.S. App. Ser. No. 10/551,504, filed December 23, 2008, 14 pages
	207	U.S. EXAMINER LORRAINE SPECTOR, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/551,504, mailed April 15, 2009, 35 pages
	208	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018506, mailed March 22, 2005, 3 pages
	209	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018506, 8 pages
	210	EPO EXAMINER ROBERT RANKIN, European Search Report for App. Ser. No. EP 04 82 0316, dated July 17, 2008, 3 pages
	211	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages
	212	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018499, dated January 26, 2006, 5 pages
	213	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed January 4, 2008, 8 pages
	214	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages
	215	FISH & RICHARDSON P.C., Response to Restriction Requirement dated January 4, 2008 in U.S. App. Ser. No. 10/582,413, filed February 4, 2008, 2 pages
	216	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,413, mailed March 31, 2008, 17 pages
	217	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 31, 2008 in U.S. App. Ser. No. 10/582,413, filed June 30, 2008, 20 pages
	218	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed June 30, 2008, 2 pages
	219	U.S. EXAMINER BRADLEY DUFFY, USPTO Notice of Informal or Non-Responsive Amendment in U.S. App. Ser. No. 10/582,413, mailed October 20, 2008, 3 pages
	220	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 12, 2008, 4 pages
	221	FISH & RICHARDSON P.C., Amendment in Reply to Notice of Informal or Non-Responsive Amendment dated October 20, 2008 in U.S. App. Ser. No. 10/582,413, filed November 17, 2008, 10 pages
	222	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 25, 2008, 4 pages
	223	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 24, 2008, 4 pages
	224	U.S. EXAMINER BRADLEY DUFFY, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed March 11, 2009, 8 pages

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Naoki Kimura *et al.*	
		Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	225	FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 11, 2009 in U.S. App. Ser. No. 10/582,413, filed April 8, 2009, 8 pages
	226	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018493, mailed March 22, 2005, 2 pages
	227	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018493, dated December 20, 2005, 7 pages
	228	EPO EXAMINER INGE KALSNER, European Search Report for App. Ser. No. EP 04 82 0305, dated October 6, 2008, 3 pages
	229	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/005152, mailed July 20, 2004, 2 pages
	230	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/005152, dated February 14, 2005, 6 pages
	231	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser. No. EP 04 72 6750, dated February 4, 2008, 3 pages
	232	U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/547,747, mailed June 1, 2009, 41 pages
	233	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/306800, mailed May 16, 2006, 4 pages
	234	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/306800, dated October 3, 2007, 6 pages
	235	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/309890, mailed July 18, 2006, 2 pages
	236	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/309890, dated November 19, 2007, 5 pages
	237	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/311625, mailed August 22, 2006, 2 pages
	238	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/311625, dated December 11, 2007, 4 pages
	239	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2007/063946, mailed August 14, 2007, 7 pages
	240	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/063946, dated January 20, 2009, 10 pages
	241	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,654, mailed May 26, 2009, 9 pages
	242	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Restriction Requirement in U.S. App. Ser. No. 10/399,518, mailed November 25, 2005, 9 pages
	243	FOLEY & LARDNER LLP, Response to Restriction Requirement dated November 25, 2005 in U.S. App. Ser. No. 10/399,518, filed December 23, 2005, 3 pages
	244	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed March 27, 2006, 38 pages
	245	FOLEY & LARDNER LLP, Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed September 26, 2006, 26 pages

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Naoki Kimura *et al.*	
	Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	246	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 11, 2006, 11 pages
	247	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 13, 2006, 11 pages
	248	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed December 28, 2006, 29 pages
	249	FOLEY & LARDNER LLP, Amendment in Reply to Action dated December 28, 2006 in U.S. App. Ser. No. 10/399,518, filed May 3, 2007, 22 pages
	250	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed June 7, 2007, 13 pages
	251	FOLEY & LARDNER LLP, Amendment in Reply to Action dated June 7, 2007 in U.S. App. Ser. No. 10/399,518, filed September 7, 2007, 9 pages
	252	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed September 27, 2007, 5 pages
	253	U.S. EXAMINER DAVID J. BLANCHARD, Interview Summary in U.S. App. Ser. No. 10/399,518, mailed November 13, 2007, 3 pages
	254	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed January 31, 2008, 14 pages
	255	FOLEY & LARDNER LLP, Amendment in Reply to Action dated January 31, 2008 in U.S. App. Ser. No. 10/399,518, filed April 30, 2008, 7 pages
	256	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed August 4, 2008, 8 pages
	257	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed November 7, 2008, 4 pages
	258	FOLEY & LARDNER LLP, Amendment in Reply to Action dated November 7, 2008 in U.S. App. Ser. No. 10/399,518, filed October 23, 2008, 8 pages
	259	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed February 17, 2009, 12 pages
	260	FOLEY & LARDNER LLP, Amendment in Reply to Action dated February 17, 2009 in U.S. App. Ser. No. 10/399,518, filed May 18, 2009, 26 pages
	261	FISH & RICHARDSON P.C., Reply to Office Action dated January 28, 2009 in U.S. App. Ser. No. 10/548,727, filed June 26, 2009, 9 pages
	262	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed June 25, 2009, 28 pages

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.